Acesso livre
Acesso livre

Medicina de Emergências

Estudo randomizado | Cateter percutâneo 14-Fr de pequeno calibre (pigtail) foi tão efetivo quanto cateteres 28 a 32-Fr em sua capacidade de drenar hemotórax traumático, sem diferença nas complicações.

30 Nov, 2021 | 12:15h

The small (14 Fr) percutaneous catheter (P-CAT) versus large (28–32 Fr) open chest tube for traumatic hemothorax: A multicenter randomized clinical trial – Trauma and Acute Care Surgery (link para o resumo – $ para o texto completo)

Revisão sistemática | Anticoagulantes para AVC isquêmico agudo.

30 Nov, 2021 | 12:09h

Resumo: Early treatment with blood-thinning drugs for people who have had a stroke – Cochrane Library

Estudo original: Anticoagulants for acute ischaemic stroke – Cochrane Library

Podcast | Alcalose metabólica e hipocalemia.

30 Nov, 2021 | 12:06h

#308 Metabolic Alkalosis and Hypokalemia: Kidney Boy Returns! – The Curbsiders

Ataque isquêmico transitório: avaliação e conduta no departamento de emergência.

30 Nov, 2021 | 12:05h

TIA: Emergency Department Evaluation and Disposition – emDocs

Conteúdos relacionados:

AHA/ASA Guideline: Prevention of stroke in patients with previous stroke and transient ischemic attack – prevention efforts should be based on the cause of the first ischemic event.

Stroke and transient ischaemic attack in over 16s: diagnosis and initial management – National Institute for Health and Care Excellence

Canadian Stroke Best Practice Recommendations for Acute Stroke Management

Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke – The BMJ

2 recent meta-analysis highlight the benefits of short term (30 days) dual antiplatelet therapy with aspirin + clopidogrel in patients within 24 hours of high-risk transient ischemic attack or mild-moderate ischemic stroke.

Prospective validation of Canadian TIA Score for subsequent stroke risk after transient ischemic attack

Systematic review: Multiple vs. fewer antiplatelet agents for preventing early recurrence after ischemic stroke or transient ischemic attack

[Comunicado de imprensa – Ainda não publicado] Dados atualizados sobre a nova pílula da Merck contra Covid (molnupiravir) mostram eficácia reduzida (30%) em evitar internação e morte, em comparação aos resultados iniciais (50%). O risco absoluto em reduzir internação e morte caiu de 7% para 3%.

29 Nov, 2021 | 11:01h

Comunicado de imprensa: Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19

Comentário: New data, analyses take some of the shine off Merck’s Covid pill – STAT

Conteúdos relacionados:

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

Comentários no Twitter

 

Revisão | Prevenção e tratamento de trombose em pacientes internados com pneumonia por COVID-19.

26 Nov, 2021 | 12:04h

Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia – The Lancet Respiratory Medicine

Revisão | Ventilação não invasiva e estratégias de oxigenação.

25 Nov, 2021 | 14:55h

Noninvasive Ventilation and Oxygenation Strategies – Surgical Clinics of North America

Revisão | Infecção fúngica invasiva associada à COVID-19.

24 Nov, 2021 | 11:34h

COVID-19-associated Invasive Fungal Infection – Open Forum Infectious Diseases

Conteúdos relacionados:

Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis.

M-A: Incidence and mortality of COVID‐19‐associated pulmonary aspergillosis – The incidence and mortality in the ICU were estimated to be 10.2% and 54.9%, respectively.

Consensus Guideline: Defining and managing COVID-19-associated pulmonary aspergillosis

Bacterial and fungal superinfections in critically ill patients with COVID-19

Invasive Fungal Disease complicating COVID-19: when it rains it pours

A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU

Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients

 

Comentário no Twitter

 

Estudo de coorte prospectivo mostrou um risco de 3,1% de tromboembolismo venoso recorrente em 90 dias em pacientes com embolia pulmonar subsegmentar tratada sem anticoagulação.

24 Nov, 2021 | 11:20h

Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation: A Multicenter Prospective Cohort Study – Annals of Internal Medicine (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

 

Dor torácica: quem precisa de exames adicionais além do ECG e da troponina?

24 Nov, 2021 | 11:15h

Chest Pain: Who Needs Additional Testing Beyond ECG and Troponin? – JACC: Case Reports

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.